APA (7th ed.) Citation

F, H., MR, H., & J, N. (2026). From Inflammation to Targeted Therapy: Leveraging Neutrophil, Platelet, RBC, and Macrophage Biology for Nanocarrier in Atherosclerosis. Current atherosclerosis reports, 28(1), . https://doi.org/10.1007/s11883-026-01394-3

Chicago Style (17th ed.) Citation

F, Heydari, Hamblin MR, and Naghinezhad J. "From Inflammation to Targeted Therapy: Leveraging Neutrophil, Platelet, RBC, and Macrophage Biology for Nanocarrier in Atherosclerosis." Current Atherosclerosis Reports 28, no. 1 (2026). https://doi.org/10.1007/s11883-026-01394-3.

MLA (9th ed.) Citation

F, Heydari, et al. "From Inflammation to Targeted Therapy: Leveraging Neutrophil, Platelet, RBC, and Macrophage Biology for Nanocarrier in Atherosclerosis." Current Atherosclerosis Reports, vol. 28, no. 1, 2026, https://doi.org/10.1007/s11883-026-01394-3.